FinBoss.io
CSEN
  • Crypto prices
  • Liquidation War
  • Crypto tools
  • Bitcoin on-chain
  • US macro
  • US stocks
    • Largest US stocks
    • Stock screener
    • Earnings calendar
    • Insider trading
    • Market heatmap
  • Markets
  • Tools
  • Guides
  • FinBot
FinBoss.io
Crypto prices
Liquidation War
Crypto tools
Altcoin Season Index
Big players (on-chain)
Bitcoin halving countdown
Bear market radar
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Largest US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Markets
Stock indices
Commodities
Forex rates
Bear market radar
Famous investors' portfolios
Tools
Dashboards
Investor dashboardTrader dashboardBeginner dashboard
Calculators
Compound interestDCA calculatorDrawdown recovery
Compare
BrokersCrypto exchanges
Přehled sekce Tools →
Guides
FinBot
CSEN
Home
Stocks
Twist Bioscience Corp
TW

Twist Bioscience Corp

TWSTNASDAQ

Stock · Data from SEC EDGAR 13F · Held by 6 of 87 tracked investors

$159.85
▲ 10.05%
Famous investorshold 6buying 0selling 0
Price (USD)
$159.85
Market cap
$10.6B
P/E ratio
–
Tracked investors holding
6 of 87
Next earnings
–

Twist Bioscience Corp at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
46out of 100
  • Valuation15
  • Growth94
  • Profitability5
  • Quality20
  • Debt100
  • Stability44
In its favour
  • ✓It has more cash than debt.
  • ✓Revenue grew 22.8% a year over 3 years.
What to watch
  • !The company is loss-making: net profit is negative.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Expensive

The company has no earnings, so the P/E cannot be calculated.

P/E
–
P/S
24.5×
EV/EBITDA
-78.5×

Is the company growing?

Growing
22
23
24
25

Revenue over 3 years grew 22.8% a year. Last year 23.2%.

Does it make money?

Loss-making
  • Cost of sales 49

Revenue and net profit (USD M)

Margins (% of revenue)

Free cash flow and capex (USD M)

Cash and debt (USD M)

Earnings per share (EPS, USD)

Latest quarters (USD M)

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 20263 Aug 2026-0.56-0.50-12%
Mar 20264 May 2026-0.62-0.54-14.8%
Dec 20252 Feb 2026-0.50-0.48-4.2%
Sep 202514 Nov 2025-0.45-0.40-12.5%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

Chart TWST

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

6
CW
Cathie Wood
ARK Investment Management
3.04%$468,083,756▼ -28.3%
RD
Ray Dalio
Bridgewater Associates
0.01%$1,918,403New position
KG
Ken Griffin
Citadel Advisors
0.01%$88,686,881▼ -29.4%
IE
Israel Englander
Millennium Management
0.01%$35,714,586▼ -1%
Šn
Švýcarská národní banka
Swiss National Bank
0.01%$11,707,744▼ -4.4%
CA
Cliff Asness
AQR Capital Management
0%$13,311,719▲ +3.7%

Frequently asked questions

How much is Twist Bioscience Corp (TWST) stock?

Twist Bioscience Corp shares trade at $159.85, +10.05% over the last trading day. The price is delayed.

What is the market cap of Twist Bioscience Corp?

The market cap of Twist Bioscience Corp is about $10.6B.

Which big investors hold Twist Bioscience Corp?

According to the latest 13F filings, 6 of 87 tracked investors hold Twist Bioscience Corp, for example Cathie Wood, Ray Dalio, Ken Griffin.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms of usePrivacy policyCookie policy

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

  • Research 21.3
  • Operations and selling 65.6
  • Taxes and other 0.0
  • Net profit -20.6
  • Out of 100 USD of revenue, -20.6 USD is left as net profit.

    Is it financially healthy?

    Yes
    Cash
    167M USD
    Debt
    109M USD
    Free CF
    -65M USD

    It has more cash than debt.

    Does it pay a dividend?

    No dividend

    The company pays no dividend. It reinvests the money or holds it.

    What do analysts expect?

    Buy
    Average target
    168.25 USD
    Vs price
    +5%

    12 analysts. Their opinion is not a recommendation by FinBoss.io.

    Which big investors hold it?

    6 of 87

    Among the tracked investors, Cathie Wood, Ray Dalio, Ken Griffin and others hold the stock according to 13F filings.

    Ratios

    P/E
    –
    Forward P/E
    -399.6×
    P/B
    22.5×
    P/S
    24.5×
    PEG
    –
    EV/EBITDA
    -78.5×
    Gross margin
    52.0%
    Operating margin
    -30.6%
    Net margin
    -31.7%
    ROE
    -29.6%
    ROA
    -13.1%
    Debt / equity
    0.2×
    Current ratio
    2.7×
    Revenue growth
    23.2%
    Earnings growth
    –
    Beta
    2.19
    Dividend
    0.00%
    Payout ratio
    –